ATL51 Antibody

Nomenclature Clarification

The term "ATL51" does not appear in peer-reviewed literature, clinical trials, or commercial antibody databases within the provided search results. Potential interpretations:

• ATL: Frequently refers to Adult T-cell Leukemia/Lymphoma in oncology literature , but no connection to "51" is documented.

• CD51: A well-characterized antigen (integrin alpha V) targeted by antibodies like RMV-7 and MAB1219 , but these are unrelated to "ATL51."

A. Antibodies Targeting CD51 (Integrin alpha V)

B. ATL-Related Antibody Therapies

• Anti-CD4 antibodies (e.g., alemtuzumab) show efficacy in ATL clinical trials .

• Anti-CD123 immunotoxins target interleukin-3 receptors in acute myeloid leukemia .

Potential Causes for Missing Data

• Typographical Error: "ATL51" may be a misinterpretation of CD51 or ATL1102 (an antisense oligonucleotide targeting CD49d in muscular dystrophy ).

• Proprietary Compound: The term might refer to an undisclosed developmental antibody not yet published.

• Species/Model Specificity: No murine or humanized antibodies with this designation are documented.

Recommendations for Further Investigation

1. Verify the compound name with original sources or patents.

2. Explore antibodies targeting integrin alpha V (CD51) or ATL-associated antigens (e.g., CD4, CD25, CCR4) as alternatives .

3. Consult regulatory databases (e.g., ClinicalTrials.gov) for unpublished studies.